Her2 expression and gene amplification is rarely detectable in patients with oral squamous cell carcinomas

Journal of Oral Pathology and Medicine

Volumn 43, Issue 4, 2014, Pages 304-308

  Hanken, Henning ^a   Gaudin, Robert ^a   Gröbe, Alexander ^a   Fraederich, Meike ^a   Eichhorn, Wolfgang ^a   Smeets, Ralf ^a   Simon, Ronald ^a   Sauter, Guido ^a   Grupp, Katharina ^a   Izbicki, Jacob R ^a   Sehner, Susanne ^a   Heiland, Max ^a   Blessmann, Marco ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Fluorescence in situ hybridization; Head and neck squamous cell carcinoma; Her2; Immunohistochemistry; Oral squamous cell carcinomas

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; TISSUE MICROARRAY; CANCER GRADING; CANCER STAGING; CHEMISTRY; COMPARATIVE STUDY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; LYMPH NODE; MIDDLE AGED; MOUTH; MOUTH TUMOR; PATHOLOGY; PHARYNX CANCER; PROCEDURES; SECONDARY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODES; MALE; MIDDLE AGED; MOUTH FLOOR; MOUTH NEOPLASMS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHARYNGEAL NEOPLASMS; PHENOTYPE; RECEPTOR, ERBB-2; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 84898059006     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12173     Document Type: Article

References (24)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Gupta S, Kong W, Peng Y, et al. Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. Int J Cancer 2009; 125: 2159-65.
3. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-16.
4. Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation. Ann Oncol 2001; 12(Suppl 1): S9-13.
5. Scheer M, Prange W, Petmecky K, et al. Evaluation of her-2/neu amplification/overexpression in OSCC with fluorescence in situ hybridization (FISH) and immunohistochemistry. Mund Kiefer Gesichtschir 2003; 7: 138-45.
6. Xia W, Lau YK, Zhang HZ, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999; 5: 4164-74.
7. Craven JM, Pavelic ZP, Stambrook PJ, et al. Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res 1992; 12: 2273-6.
8. Field JK, Spandidos DA, Yiagnisis M, et al. C-erbB-2 expression in squamous cell carcinoma of the head and neck. Anticancer Res 1992; 12: 613-9.
9. Krecicki T, Jelen M, Zalesska-Krecicka M. C-erbB-2 immunostaining in laryngeal cancer. Acta Otolaryngol 1999; 119: 392-5.
10. Khan AJ, King BL, Smith BD, et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 2002; 8: 540-8.
11. Beckhardt RN, Kiyokawa N, Xi L, et al. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1995; 121: 1265-70.
12. Sardari Y, Pardis S, Tadbir AA, et al. HER2/neu expression in head and neck squamous cell carcinoma patients is not significantly elevated. Asian Pac J Cancer Prev 2012; 13: 2891-6.
13. Ali MA, Gunduz M, Gunduz E, et al. Expression and mutation analysis of her2 in head and neck squamous cell carcinoma. Cancer Invest 2010; 28: 495-500.
14. Cavalot A, Martone T, Roggero N, et al. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck 2007; 29: 655-64.
15. Fong Y, Chou SJ, Hung KF, et al. An investigation of the differential expression of Her2/neu gene expression in normal oral mucosa, epithelial dysplasia, and oral squamous cell carcinoma in Taiwan. J Chin Med Assoc 2008; 71: 123-7.
16. Dragomir LP, Margaritescu C, Florescu A, et al. The immunoexpression of EGFR and Her2/neu in oral squamous carcinoma. Rom J Morphol Embryol 2012; 53: 597-601.
17. Seifi S, Shafaei SN, Nosrati K, et al. Lack of elevated HER2/neu expression in epithelial dysplasia and oral squamous cell carcinoma in Iran. Asian Pac J Cancer Prev 2009; 10: 661-4.
18. Ekberg T, Nestor M, Engstrom M, et al. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Int J Oncol 2005; 26: 1177-85.
19. Tse GM, Yu KH, Chan AW, et al. HER2 expression predicts improved survival in patients with cervical node-positive head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2009; 141: 467-73.
20. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-45.
21. Crowe DL, Hacia JG, Hsieh CL, et al. Molecular pathology of head and neck cancer. Histol Histopathol 2002; 17: 909-14.
22. Vergara-Lluri ME, Moatamed NA, Hong E, et al. High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines. Mod Pathol 2012; 25: 1326-32.
23. Kondo N, Tsukuda M, Sakakibara A, et al. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines. Int J Oncol 2012; 40: 1805-12.
24. Kondo N, Ishiguro Y, Kimura M, et al. Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. Oncol Rep 2008; 20: 373-8.